GANX - Gain Therapeutics, Inc. Stock Price, Fair Value and News

2.85USD+0.17 (+6.34%)Delayed as of 09 May 2024, 09:50 am ET

Market Summary

USD2.85+0.17

Delayedas of 09 May 2024, 09:50 am

6.34%

GANX Alerts

1 major insider buys recently.

GANX Stock Price

View Fullscreen

GANX RSI Chart

GANX Valuation

Market Cap

43.5M

Price/Earnings (Trailing)

-1.95

Price/Sales (Trailing)

787.76

EV/EBITDA

-1.49

Price/Free Cashflow

-2.3

GANX Price/Sales (Trailing)

GANX Profitability

EBT Margin

-40210.67%

Return on Equity

-177.03%

Return on Assets

-119.66%

Free Cashflow Yield

-43.4%

GANX Fundamentals

GANX Revenue

Revenue (TTM)

55.2K

GANX Earnings

Earnings (TTM)

-22.3M

Earnings Growth (Yr)

-1.06%

Earnings Growth (Qtr)

-0.12%

Breaking Down GANX Revenue

52 Week Range

2.655.45

(Low)(High)

Last 7 days

-10.4%

Last 30 days

-22.4%

Last 90 days

-45.0%

Trailing 12 Months

-48.4%

How does GANX drawdown profile look like?

GANX Financial Health

Current Ratio

3.59

Debt/Equity

0.04

Debt/Cashflow

-42.01

GANX Investor Care

Shares Dilution (1Y)

8.64%

Diluted EPS (TTM)

-1.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	150.3K	55.2K	55.2K	55.2K
2022	204.7K	210.7K	183.3K	140.1K
2021	27.5K	110.3K	130.9K	165.0K
2020	0	0	0	28.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Gain Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	riley jeffrey scott	bought	115,770	3.859	30,000	-
Mar 26, 2024	alder matthias	sold (taxes)	-24,705	4.06	-6,085	chief executive officer
Mar 26, 2024	alder matthias	acquired	-	-	20,212	chief executive officer
Dec 21, 2023	alder matthias	sold	-506	2.46	-206	chief executive officer
Dec 20, 2023	alder matthias	acquired	-	-	637	chief executive officer
Dec 07, 2023	alder matthias	sold	-4,550	2.5	-1,820	chief executive officer
Oct 01, 2023	alder matthias	acquired	-	-	825	chief executive officer
Sep 20, 2023	richman eric i	acquired	-	-	54,900	-
Sep 20, 2023	alder matthias	acquired	-	-	2,550	chief executive officer
Jul 01, 2023	alder matthias	acquired	-	-	3,300	chief executive officer

Which funds bought or sold GANX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	24.82	49,701	162,344	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	67,000	67,000	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	993	902,604	980,272	-%
Mar 11, 2024	VANGUARD GROUP INC	added	25.76	58,059	288,577	-%
Mar 01, 2024	Creekmur Asset Management LLC	new	-	14,497	14,497	-%
Feb 14, 2024	GREENLIGHT CAPITAL INC	unchanged	-	-8,827	1,921,160	0.09%
Feb 14, 2024	GROUP ONE TRADING, L.P.	added	103	6,597	12,854	-%
Feb 14, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	unchanged	-	-871	189,697	0.01%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	41,674	41,674	-%

Are Funds Buying or Selling GANX?

Are funds buying GANX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GANX

No. of Funds

GANX Alerts

1 major insider buys recently.

Recent SEC filings of Gain Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 08, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	3	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report

Peers (Alternatives to Gain Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.8	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.13	14.32	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Gain Therapeutics, Inc. News

Latest updates

Gain Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-	-	-	-	55,180	-	-	95,102	45,006	43,208	27,345	89,173	5,269	9,139	6,696	6,373	6,673
Operating Expenses	-9.8%	4,407,230	4,885,005	7,731,114	5,284,964	4,561,199	4,750,984	5,271,487	3,333,483	3,251,977	4,663,270	3,603,736	2,472,184	1,624,774	825,785	538,838	518,933
S&GA Expenses	-19.2%	2,033,247	2,517,523	3,743,171	2,493,759	2,287,357	2,786,200	2,689,263	1,777,043	1,779,504	2,186,531	1,810,228	1,050,675	649,162	398,320	99,970	101,674
R&D Expenses	0.3%	2,373,983	2,367,482	3,987,943	2,791,205	2,273,842	1,964,784	2,582,224	1,556,440	1,472,473	2,476,739	1,793,508	1,421,509	975,612	427,465	438,868	417,259
EBITDA Margin	-0.8%	-391	-388	-385	-124	-121	-86.55	-76.58	-71.71	-83.99	-93.82	-76.40	-197	-123	-	-	-
Interest Expenses	0.3%	106,270	106,000	129,929	152,035	163,777	153,332	59,899	-1,651	267	4,918	5,901	1,408	6,895	7.00	-1,517	-1,747
Income Taxes	-32.4%	14,502	21,456	26,589	16,728	78,105	4,048	9,146	1,677	-8,244	5,114	3,660	3,479	-1,368	885	4,523	1,347
Earnings Before Taxes	-0.3%	-4,709,467	-4,696,807	-7,661,380	-5,120,591	-4,596,361	-4,554,161	-5,076,274	-3,270,966	-3,228,177	-4,658,419	-3,553,033	-2,446,968	-1,657,049	-793,486	-538,839	-582,921
EBT Margin	-0.5%	-402	-400	-397	-128	-124	-87.99	-77.06	-71.85	-84.16	-94.06	-76.63	-197	-123	-	-	-
Net Income	-0.1%	-4,723,969	-4,718,263	-7,687,969	-5,137,319	-4,674,466	-4,558,209	-5,085,420	-3,272,643	-3,219,933	-4,663,533	-3,556,693	-2,450,447	-1,655,681	-794,371	-543,362	-584,268
Net Income Margin	-0.2%	-403	-402	-399	-129	-125	-88.02	-77.10	-71.86	-84.19	-94.15	-76.69	-198	-123	-	-	-
Free Cashflow	-42.7%	-5,660,379	-3,966,715	-5,078,543	-4,274,594	-3,961,792	-3,346,255	-5,095,610	-2,455,216	-4,157,463	-2,224,461	-3,239,563	-2,838,395	-1,322,768	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	32.0%	18,609	14,097	18,261	21,323	24,099	28,326	31,890	37,599	38,985	42,562	45,353	48,041	9,604
Current Assets	34.3%	17,779	13,242	17,308	19,322	21,091	24,349	25,833	36,392	37,722	41,555	44,335	47,384	8,988
Cash Equivalents	176.1%	11,795	4,273	6,320	5,988	7,312	10,909	14,336	34,369	36,912	41,015	43,205	46,636	7,504
Net PPE	-1.1%	126	127	139	145	144	137	139	107	106	103	75.00	55.00	30.00
Liabilities	-10.9%	6,031	6,767	7,168	6,184	5,220	5,663	4,873	5,771	4,168	-	-	-	3,402
Current Liabilities	-14.1%	4,950	5,763	5,588	5,155	4,125	4,332	3,410	4,217	2,553	3,577	2,451	2,327	2,115
Long Term Debt	3.2%	449	435	467	478	495	484	542	561	590	620	647	678	716
LT Debt, Current	8.7%	119	109	112	109	108	101	84.00	87.00	104	87.00	65.00	44.00	23.00
LT Debt, Non Current	3.2%	449	435	467	478	495	484	542	561	590	620	647	678	716
Shareholder's Equity	71.6%	12,578	7,331	11,093	15,139	18,880	22,663	27,017	31,828	34,818	37,545	41,389	44,464	6,202
Retained Earnings	-Infinity%	-38,516	-	-	-38,516	-20,925	-20,925	-20,925	-20,925	-7,034	-7,034	-7,034	-7,034	-3,457
Additional Paid-In Capital	15.5%	73,113	63,299	62,299	58,695	57,359	56,800	56,445	56,139	55,832	55,362	54,594	54,105	13,389
Shares Outstanding	26.8%	16,207	12,783	12,632	12,087	11,883	11,883	11,883	11,883	11,883	9,587	11,876	4,869	-
Float	-	-	-	56,600	-	-	-	38,800	-	-	-	118,700	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-42.7%	-5,660	-3,966	-5,021	-4,217	-3,904	-3,289	-5,051	-2,447	-4,146	-2,192	-3,217	-2,809	-1,308	-755	-424	-752
Share Based Compensation	-38.8%	555	907	1,231	565	559	356	306	307	286	251	192	111	-	-	-	-
Cashflow From Investing	62.9%	3,142	1,929	3,045	2,107	134	-11.41	-14,889	-7.82	-11.10	-32.12	-22.50	-28.49	-14.55	-1.42	38*	-4.90
Cashflow From Financing	7009.7%	9,561	134	2,197	749	-21.58	-20.58	1.00	-37.97	-9.73	-	-213	41,990	-440	9,545	-10.55	1,393

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GANX Income Statement

2023-12-31

Consolidated Statement of Operations - USD ($)	12 Months Ended
Consolidated Statement of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Collaboration revenues	$ 55,180	$ 132,640
Other income		7,468
Total revenues	55,180	140,108
Operating expenses:
Research and development	(11,520,613)	(8,377,290)
General and administrative	(10,787,700)	(9,539,863)
Total operating expenses	(22,308,313)	(17,917,153)
Loss from operations	(22,253,133)	(17,777,045)
Other income (expense):
Interest income, net	494,234	375,357
Foreign exchange loss, net	(429,346)	(96,074)
Loss before income tax	(22,188,245)	(17,497,762)
Income tax	(79,275)	(92,976)
Net loss	$ (22,267,520)	$ (17,590,738)
Net loss per shares:
Net loss per share attributable to common stockholders - Basic	$ (1.71)	$ (1.48)
Net loss per share attributable to common stockholders - Diluted	$ (1.71)	$ (1.48)
Weighted average common stock - Basic	13,011,361	11,883,368
Weighted average common stock - Diluted	13,011,361	11,883,368

GANX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 11,794,949	$ 7,311,611
Marketable securities - current	4,999,704	12,826,954
Tax credits	242,577	103,877
Prepaid expenses and other current assets	741,638	848,854
Total current assets	17,778,868	21,091,296
Non-current assets:
Marketable securities - non current		1,941,488
Property and equipment, net	125,962	144,379
Internal-use software	193,375	213,967
Operating lease - right of use assets	459,215	659,933
Restricted cash	34,021	30,818
Long-term deposits and other non-current assets	17,890	17,506
Total non-current assets	830,463	3,008,091
Total assets	18,609,331	24,099,387
Current liabilities:
Accounts payable	1,318,965	1,626,100
Operating lease liability - current	229,693	229,080
Other current liabilities	2,160,366	2,106,756
Deferred income - current	1,122,138	55,180
Loans - current	118,797	108,135
Total current liabilities	4,949,959	4,125,251
Non-current liabilities:
Defined benefit pension plan	307,454	157,580
Operating lease liability - non-current	229,855	441,784
Deferred income - non-current	94,786
Loans - non-current	449,053	495,258
Total non-current liabilities	1,081,148	1,094,622
Total liabilities	6,031,107	5,219,873
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of December 31, 2023 and 2022
Common stock, $0.0001 par value: 50,000,000 shares authorized; 16,206,680 shares issued and outstanding as of December 31, 2023 and 11,883,368 shares issued and outstanding as of December 31, 2022	1,621	1,189
Additional paid-in capital	73,113,079	57,358,895
Accumulated other comprehensive income	247,241	35,627
Accumulated deficit	(38,516,197)	(20,925,459)
Loss of the period	(22,267,520)	(17,590,738)
Total stockholders' equity	12,578,224	18,879,514
Total liabilities and stockholders' equity	$ 18,609,331	$ 24,099,387

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

CEO	Mr. Matthias Alder LIC. IUR., LL.M.
WEBSITE	gaintherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	28

Gain Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Gain Therapeutics, Inc.? What does GANX stand for in stocks?

GANX is the stock ticker symbol of Gain Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gain Therapeutics, Inc. (GANX)?

As of Wed May 08 2024, market cap of Gain Therapeutics, Inc. is 43.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GANX stock?

You can check GANX's fair value in chart for subscribers.

What is the fair value of GANX stock?

You can check GANX's fair value in chart for subscribers. The fair value of Gain Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gain Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GANX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gain Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GANX is over valued or under valued. Whether Gain Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Gain Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GANX.

What is Gain Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, GANX's PE ratio (Price to Earnings) is -1.95 and Price to Sales (PS) ratio is 787.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GANX PE ratio will change depending on the future growth rate expectations of investors.